Breast Cancer
Conditions
Interventions
Group 1:nab-P as neoadjuvant therapy
Group 2:paclitaxel as neoadjuvant therapy
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. breast cancer is confirmed by the mammography, and the immunohistochemical results of cancer tissues are negative for estrogen receptor, progesterone receptor and anti-human epidermal growth factor receptor 2; 2. positive for axillary lymph node metastasis; 3. Aged 18-70 years female; 4. patients have good compliance with the planned treatment, who are volunteer to participate in the study, are willing to be treated with solvent-based paclitaxel or nab-P at random, and provide written informed consent with the premise of fully understanding the study protocol.
Exclusion criteria
Exclusion criteria: 1. pregnant and lactating women; 2. distant metastasis; 3. patients with a history of other cancers or who have received radiotherapy on the chest; 4. abnormalities in blood tests or presence of other symptoms of infection; 5. allergy to paclitaxel; 6. patients who have psychotropic drug abuse until now or those with a history of mental disorders; 7. abnormalities in important organs such as the heart, lung, liver and kidney; 8. patients who have participated in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of tumor stem cells in the lesion;Progression-free survival;Overall survival;Adverse events; | — |
Countries
China
Contacts
Public ContactCaigang Liu
Shengjing Hospital of China Medical University
Outcome results
None listed